Role of STAT3 in Transformation and Drug Resistance in CML
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Chronic myeloid leukemia (CML) is initially driven by the bcr-abl fusion oncoprotein. The identification of bcr-abl led to the discovery and rapid translation into the clinic of bcr-abl kinase inhibitors. Although, bcr-abl inhibitors are efficacious, experimental evidence indicates that targeting bcr-abl is not sufficient for elimination of minimal residual disease found within the bone marrow (BM). Experimental evidence indicates that the failure to eliminate the leukemic stem cell contributes to persistent minimal residual disease. Thus curative strategies will likely need to focus on strategies where bcr-abl inhibitors are given in combination with agents that specifically target the leukemic stem cell or the leukemic stem cell niche. One potential target to be exploited is the Janus kinase (JAK)/signal transducers and activators of transcription 3 (STAT3) pathway. Recently using STAT3 conditional knock-out mice it was shown that STAT3 is critical for initiating the disease. Interestingly, in the absence of treatment, STAT3 was not shown to be required for maintenance of the disease, suggesting that STAT3 is required only in the tumor initiating stem cell population (Hoelbl et al., 2010). In the context of the BM microenvironment, STAT3 is activated in a bcr-abl independent manner by the cytokine milieu. Activation of JAK/STAT3 was shown to contribute to cell survival even in the event of complete inhibition of bcr-abl activity within the BM compartment. Taken together, these studies suggest that JAK/STAT3 is an attractive therapeutic target for developing strategies for targeting the JAK-STAT3 pathway in combination with bcr-abl kinase inhibitors and may represent a viable strategy for eliminating or reducing minimal residual disease located in the BM in CML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“These stem cells where then transduced with a tetracycline regulated expression of bcr–abl vector employing a promoter that ensures 100% expression of bcr–abl in all the differentiated cells (Gossen and Bujard, 1992; Nakano et al., 1994).”
BackgroundPrinciples of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 2×
“Irrespective of the activating kinase protein, STAT3 gets phosphorylated at the Tyr705 residue in the C-terminal domain and this phosphorylation leads to its activation (Heinrich et al., 1998, 2003; Quesnelle et al., 2007).”
BackgroundSTATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 2×
“Irrespective of the activating kinase protein, STAT3 gets phosphorylated at the Tyr705 residue in the C-terminal domain and this phosphorylation leads to its activation (Heinrich et al., 1998, 2003; Quesnelle et al., 2007).”
BackgroundZhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070 · cited 3×
“…signals from cytokine-stimulated cell surface receptors to the nucleus, where it was capable of selectively binding to a palindromic Interferon (IFN)-γ-activated sequence element and induce transcription of acute-phase genes (Akira et al., 1994; Lutticken et al., 1994; Zhong et al., 1994).”
BackgroundWen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974 · cited 1×
“In addition, STAT3 can also be phosphorylated on the Ser727 residue, located in the transactivation domain, which allows for the maximal activation of transcription of genes (Zhang et al., 1995; Wen et al., 1995).”
BackgroundTargeted disruption of the mouse Stat3 gene leads to early embryonic lethality
Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T., & Akira, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3801 · Cited by 1,323 · cited 1×
“Unlike all other STAT family members, targeted disruption of STAT3 gene, lead to early embryonic lethality (Takeda et al., 1997).”
BackgroundTakeda, K., Clausen, B. E., Kaisho, T., Tsujimura, T., Terada, N., Förster, I., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80005-9 · Cited by 1,220
Akira, S., Nishio, Y., Inoue, M., Wang, X.-J., We, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., & Kishimoto, T. (1994) · Cell · doi:10.1016/0092-8674(94)90235-6 · Cited by 1,019 · cited 1×
“…signals from cytokine-stimulated cell surface receptors to the nucleus, where it was capable of selectively binding to a palindromic Interferon (IFN)-γ-activated sequence element and induce transcription of acute-phase genes (Akira et al., 1994; Lutticken et al., 1994; Zhong et al., 1994).”
BackgroundSpecific Inhibition of Stat3 Signal Transduction by PIAS3
Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., & Shuai, K. (1997) · Science · doi:10.1126/science.278.5344.1803 · Cited by 980 · cited 1×
“PIAS, specifically PIAS3, can bind the dimeric activated STAT3 and block the DNAbinding ability of STAT3 (Chung et al., 1997).”
BackgroundLütticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., et al. (1994) · Science · doi:10.1126/science.8272872 · Cited by 814
Shuai, K., Horvath, C. M., Huang, L. H. T., Qureshi, S. A., Cowburn, D., & Darnell, J. E. (1994) · Cell · doi:10.1016/0092-8674(94)90357-3 · Cited by 807
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
The Stat family in cytokine signaling
Ihle, J. N. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00199-x · Cited by 713 · cited 1×
“STAT3 can be activated by a variety of diverse agents ranging from cytokines, growth factors, oncogenes, non-receptor tyrosine kinases to even peptides like angiotensin II (Marrero et al., 1995; Herrington et al., 2000, Reddy et al., 2000; Ihle, 2001).”
BackgroundStat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation
Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., & Jove, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2545 · Cited by 651
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · cited 2×
“REVIEW ARTICLE published: 10 April 2012 doi: 10.3389/fonc.2012.00030 Role of STAT3 in transformation and drug resistance in CML”
BackgroundInfluentialStat3 Activation Is Required for Cellular Transformation by v- src
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., & Darnell, J. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2553 · Cited by 614
Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., & Akira, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4652 · Cited by 584
Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
You, M., Yu, D.-H., & Feng, G.-S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.2416 · Cited by 364 · cited 1×
“Finally, SHP-1 and SHP-2 have antagonistic biological functions in cells, in that, SHP-1 is a negative transducer while SHP-2 is a positive transducer of growth factor signaling pathway (Qu et al., 1999; You et al., 1999; Wang et al., 2006; Chong and Maiese, 2007).”
BackgroundReynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335
STAT3 is required for Flt3L-dependent dendritic cell differentiation
Laouar, Y., Welte, T., Fu, X.-Y., & Flavell, R. A. (2003) · Immunity · doi:10.1016/s1074-7613(03)00332-7 · Cited by 334 · cited 1×
“(e) In the dendritic cell compartment deletion of STAT3 abrogates the effects of Flt3L on dendritic cell development and results in absence of dendritic cell progenitors and thus results in a decrease in the dendritic cell compartment (Laouar et al., 2003).”
BackgroundZhang, T., Kee, W. H., Seow, K. T., Fung, W., & Cao, X. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.19.7132-7139.2000 · Cited by 150
Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells
Fornek, J. L., Tygrett, L. T., Waldschmidt, T. J., Poli, V., Rickert, R. C., & Kansas, G. S. (2006) · Blood · doi:10.1182/blood-2005-07-2871 · Cited by 148 · cited 1×
“STAT3 is also very critical in the T-cell-dependent terminal differentiation of B cells (Fornek et al., 2006).”
BackgroundUnique effects of Stat3 on the early phase of hematopoietic stem cell regeneration
Chung, Y.-J., Park, B.-B., Kang, Y.-J., Kim, T.-M., Eaves, C. J., & Oh, I.-H. (2006) · Blood · doi:10.1182/blood-2006-01-010199 · Cited by 107
STAT3 positively regulates an early step in B-cell development
Chou, W.-C., Levy, D. E., & Lee, C.-K. (2006) · Blood · doi:10.1182/blood-2006-05-024430 · Cited by 94
Nucleocytoplasmic shuttling of persistently activated STAT3
Herrmann, A., Vogt, M., Mönnigmann, M., Clahsen, T., Sommer, U., Haan, S., Poli, V., Heinrich, P. C., & Müller-Newen, G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03482 · Cited by 94 · cited 2×
“A unique PTP is the nuclear PTP TC45 which dephosphorylates STAT3 dimers that are present within the nucleus and thereby terminates STAT3-mediated transcription (Herrmann et al., 2007).”
Background
Cited by
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Lee, E., Fertig, E. J., Jin, K., Sukumar, S., Pandey, N. B., & Popel, A. S. (2014) · Nature Communications · doi:10.1038/ncomms5715 · Cited by 197
Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
Zhang, T., Li, J., Yin, F., Lin, B., Wang, Z., Xu, J., Wang, H., Zuo, D., Wang, G., Hua, Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.270 · Cited by 132
Low c-Kit expression identifies primitive, therapy-resistant CML stem cells
Shah, M., Kumar, H., Qiu, S., Li, H., Harris, M., He, J., Abraham, A., Crossman, D. K., Paterson, A., Welner, R. S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.157421 · Cited by 11
Metadata
- Authors
- Nair, R. R., Tolentino, J. H., & Hazlehurst, L. A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 2
- Pages
- 30-30
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2134259065
- Cited by
- 56
- References
- 27
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.